The global point of care testing market size accounted for USD 39.64 billion in 2024, grew to USD 44.48 billion in 2025 and is predicted to surpass around USD 125.33 billion by 2034, representing a healthy CAGR of 12.20% between 2024 and 2034. The North America point of care testing market size is calculated at USD 18.23 billion in 2024 and is expected to grow at a fastest CAGR of 12.31% during the forecast year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Point-of-Care Testing (POCT) Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Point-of-Care Testing (POCT) Market, by Product Type, 2024-2034
8.1.1. Covid -19 testing kits
8.1.1.1. Market Revenue and Forecast (2021-2034)
8.1.2. Glucose monitoring products
8.1.2.1. Market Revenue and Forecast (2021-2034)
8.1.3. Cardiometabolic Monitoring Products
8.1.3.1. Market Revenue and Forecast (2021-2034)
8.1.4. Infectious disease testing products
8.1.4.1. Market Revenue and Forecast (2021-2034)
8.1.5. Coagulation monitoring products
8.1.5.1. Market Revenue and Forecast (2021-2034)
8.1.6. Pregnancy and fertility testing products
8.1.6.1. Market Revenue and Forecast (2021-2034)
8.1.7. Pregnancy testing products
8.1.7.1. Market Revenue and Forecast (2021-2034)
8.1.8. Fertility testing products
8.1.8.1. Market Revenue and Forecast (2021-2034)
8.1.9. Cancer marker testing products
8.1.9.1. Market Revenue and Forecast (2021-2034)
8.1.10. Urinanalysis testing products
8.1.10.1. Market Revenue and Forecast (2021-2034)
8.1.11. Cholestrol testing products
8.1.11.1. Market Revenue and Forecast (2021-2034)
8.1.12. Hematology testing products
8.1.12.1. Market Revenue and Forecast (2021-2034)
8.1.13. Drugs-of-abuse testing products
8.1.13.1. Market Revenue and Forecast (2021-2034)
8.1.14. Fecal Occult testing products
8.1.14.1. Market Revenue and Forecast (2021-2034)
8.1.15. Others
8.1.15.1. Market Revenue and Forecast (2021-2034)
9.1. Point-of-Care Testing (POCT) Market, by Platform, 2024-2034
9.1.1. Lateral Flow Assays
9.1.1.1. Market Revenue and Forecast (2021-2034)
9.1.2. Dipsticks
9.1.2.1. Market Revenue and Forecast (2021-2034)
9.1.3. Microfluids
9.1.3.1. Market Revenue and Forecast (2021-2034)
9.1.4. Molecular Diagnostics
9.1.4.1. Market Revenue and Forecast (2021-2034)
9.1.5. Immunoassays
9.1.5.1. Market Revenue and Forecast (2021-2034)
10.1. Point-of-Care Testing (POCT) Market, by Mode of Purchase, 2024-2034
10.1.1. OTC products
10.1.1.1. Market Revenue and Forecast (2021-2034)
10.1.2. Prescribed based products
10.1.2.1. Market Revenue and Forecast (2021-2034)
11.1. Point-of-Care Testing (POCT) Market, by Testing Type, 2024-2034
11.1.1. Immunoassays
11.1.1.1. Market Revenue and Forecast (2021-2034)
11.1.2. Cell-Based Assays
11.1.2.1. Market Revenue and Forecast (2021-2034)
11.1.3. Nucleic Acid Amplification Testing
11.1.3.1. Market Revenue and Forecast (2021-2034)
11.1.4. Clinical Chemistry Assays
11.1.4.1. Market Revenue and Forecast (2021-2034)
11.1.5. Hematology
11.1.5.1. Market Revenue and Forecast (2021-2034)
12.1. Point-of-Care Testing (POCT) Market, by End-User, 2024-2034
12.1.1. Clinical laboratories
12.1.1.1. Market Revenue and Forecast (2021-2034)
12.1.2. Ambulatory care facilities and physician offices
12.1.2.1. Market Revenue and Forecast (2021-2034)
12.1.3. Pharmacies, retail clinics & E-comm platforms
12.1.3.1. Market Revenue and Forecast (2021-2034)
12.1.4. Hospitals, Critical care centres, Urgent care centres
12.1.4.1. Market Revenue and Forecast (2021-2034)
12.1.5. Home care & self-testing
12.1.5.1. Market Revenue and Forecast (2021-2034)
13.1. North America
13.1.1. Market Revenue and Forecast, by Product Type (2021-2034)
13.1.2. Market Revenue and Forecast, by Platform (2021-2034)
13.1.3. Market Revenue and Forecast, by Mode of Purchase (2021-2034)
13.1.4. Market Revenue and Forecast, by Testing Type (2021-2034)
13.1.5. Market Revenue and Forecast, by End-User (2021-2034)
13.1.6. U.S.
13.1.6.1. Market Revenue and Forecast, by Product Type (2021-2034)
13.1.6.2. Market Revenue and Forecast, by Platform (2021-2034)
13.1.6.3. Market Revenue and Forecast, by Mode of Purchase (2021-2034)
13.1.6.4. Market Revenue and Forecast, by Testing Type (2021-2034)
13.1.6.5. Market Revenue and Forecast, by End-User (2021-2034)
13.1.7. Rest of North America
13.1.7.1. Market Revenue and Forecast, by Product Type (2021-2034)
13.1.7.2. Market Revenue and Forecast, by Platform (2021-2034)
13.1.7.3. Market Revenue and Forecast, by Mode of Purchase (2021-2034)
13.1.7.4. Market Revenue and Forecast, by Testing Type (2021-2034)
13.1.7.5. Market Revenue and Forecast, by End-User (2021-2034)
13.2. Europe
13.2.1. Market Revenue and Forecast, by Product Type (2021-2034)
13.2.2. Market Revenue and Forecast, by Platform (2021-2034)
13.2.3. Market Revenue and Forecast, by Mode of Purchase (2021-2034)
13.2.4. Market Revenue and Forecast, by Testing Type (2021-2034)
13.2.5. Market Revenue and Forecast, by End-User (2021-2034)
13.2.6. UK
13.2.6.1. Market Revenue and Forecast, by Product Type (2021-2034)
13.2.6.2. Market Revenue and Forecast, by Platform (2021-2034)
13.2.6.3. Market Revenue and Forecast, by Mode of Purchase (2021-2034)
13.2.7. Market Revenue and Forecast, by Testing Type (2021-2034)
13.2.8. Market Revenue and Forecast, by End-User (2021-2034)
13.2.9. Germany
13.2.9.1. Market Revenue and Forecast, by Product Type (2021-2034)
13.2.9.2. Market Revenue and Forecast, by Platform (2021-2034)
13.2.9.3. Market Revenue and Forecast, by Mode of Purchase (2021-2034)
13.2.10. Market Revenue and Forecast, by Testing Type (2021-2034)
13.2.11. Market Revenue and Forecast, by End-User (2021-2034)
13.2.12. France
13.2.12.1. Market Revenue and Forecast, by Product Type (2021-2034)
13.2.12.2. Market Revenue and Forecast, by Platform (2021-2034)
13.2.12.3. Market Revenue and Forecast, by Mode of Purchase (2021-2034)
13.2.12.4. Market Revenue and Forecast, by Testing Type (2021-2034)
13.2.13. Market Revenue and Forecast, by End-User (2021-2034)
13.2.14. Rest of Europe
13.2.14.1. Market Revenue and Forecast, by Product Type (2021-2034)
13.2.14.2. Market Revenue and Forecast, by Platform (2021-2034)
13.2.14.3. Market Revenue and Forecast, by Mode of Purchase (2021-2034)
13.2.14.4. Market Revenue and Forecast, by Testing Type (2021-2034)
13.2.15. Market Revenue and Forecast, by End-User (2021-2034)
13.3. APAC
13.3.1. Market Revenue and Forecast, by Product Type (2021-2034)
13.3.2. Market Revenue and Forecast, by Platform (2021-2034)
13.3.3. Market Revenue and Forecast, by Mode of Purchase (2021-2034)
13.3.4. Market Revenue and Forecast, by Testing Type (2021-2034)
13.3.5. Market Revenue and Forecast, by End-User (2021-2034)
13.3.6. India
13.3.6.1. Market Revenue and Forecast, by Product Type (2021-2034)
13.3.6.2. Market Revenue and Forecast, by Platform (2021-2034)
13.3.6.3. Market Revenue and Forecast, by Mode of Purchase (2021-2034)
13.3.6.4. Market Revenue and Forecast, by Testing Type (2021-2034)
13.3.7. Market Revenue and Forecast, by End-User (2021-2034)
13.3.8. China
13.3.8.1. Market Revenue and Forecast, by Product Type (2021-2034)
13.3.8.2. Market Revenue and Forecast, by Platform (2021-2034)
13.3.8.3. Market Revenue and Forecast, by Mode of Purchase (2021-2034)
13.3.8.4. Market Revenue and Forecast, by Testing Type (2021-2034)
13.3.9. Market Revenue and Forecast, by End-User (2021-2034)
13.3.10. Japan
13.3.10.1. Market Revenue and Forecast, by Product Type (2021-2034)
13.3.10.2. Market Revenue and Forecast, by Platform (2021-2034)
13.3.10.3. Market Revenue and Forecast, by Mode of Purchase (2021-2034)
13.3.10.4. Market Revenue and Forecast, by Testing Type (2021-2034)
13.3.10.5. Market Revenue and Forecast, by End-User (2021-2034)
13.3.11. Rest of APAC
13.3.11.1. Market Revenue and Forecast, by Product Type (2021-2034)
13.3.11.2. Market Revenue and Forecast, by Platform (2021-2034)
13.3.11.3. Market Revenue and Forecast, by Mode of Purchase (2021-2034)
13.3.11.4. Market Revenue and Forecast, by Testing Type (2021-2034)
13.3.11.5. Market Revenue and Forecast, by End-User (2021-2034)
13.4. MEA
13.4.1. Market Revenue and Forecast, by Product Type (2021-2034)
13.4.2. Market Revenue and Forecast, by Platform (2021-2034)
13.4.3. Market Revenue and Forecast, by Mode of Purchase (2021-2034)
13.4.4. Market Revenue and Forecast, by Testing Type (2021-2034)
13.4.5. Market Revenue and Forecast, by End-User (2021-2034)
13.4.6. GCC
13.4.6.1. Market Revenue and Forecast, by Product Type (2021-2034)
13.4.6.2. Market Revenue and Forecast, by Platform (2021-2034)
13.4.6.3. Market Revenue and Forecast, by Mode of Purchase (2021-2034)
13.4.6.4. Market Revenue and Forecast, by Testing Type (2021-2034)
13.4.7. Market Revenue and Forecast, by End-User (2021-2034)
13.4.8. North Africa
13.4.8.1. Market Revenue and Forecast, by Product Type (2021-2034)
13.4.8.2. Market Revenue and Forecast, by Platform (2021-2034)
13.4.8.3. Market Revenue and Forecast, by Mode of Purchase (2021-2034)
13.4.8.4. Market Revenue and Forecast, by Testing Type (2021-2034)
13.4.9. Market Revenue and Forecast, by End-User (2021-2034)
13.4.10. South Africa
13.4.10.1. Market Revenue and Forecast, by Product Type (2021-2034)
13.4.10.2. Market Revenue and Forecast, by Platform (2021-2034)
13.4.10.3. Market Revenue and Forecast, by Mode of Purchase (2021-2034)
13.4.10.4. Market Revenue and Forecast, by Testing Type (2021-2034)
13.4.10.5. Market Revenue and Forecast, by End-User (2021-2034)
13.4.11. Rest of MEA
13.4.11.1. Market Revenue and Forecast, by Product Type (2021-2034)
13.4.11.2. Market Revenue and Forecast, by Platform (2021-2034)
13.4.11.3. Market Revenue and Forecast, by Mode of Purchase (2021-2034)
13.4.11.4. Market Revenue and Forecast, by Testing Type (2021-2034)
13.4.11.5. Market Revenue and Forecast, by End-User (2021-2034)
13.5. Latin America
13.5.1. Market Revenue and Forecast, by Product Type (2021-2034)
13.5.2. Market Revenue and Forecast, by Platform (2021-2034)
13.5.3. Market Revenue and Forecast, by Mode of Purchase (2021-2034)
13.5.4. Market Revenue and Forecast, by Testing Type (2021-2034)
13.5.5. Market Revenue and Forecast, by End-User (2021-2034)
13.5.6. Brazil
13.5.6.1. Market Revenue and Forecast, by Product Type (2021-2034)
13.5.6.2. Market Revenue and Forecast, by Platform (2021-2034)
13.5.6.3. Market Revenue and Forecast, by Mode of Purchase (2021-2034)
13.5.6.4. Market Revenue and Forecast, by Testing Type (2021-2034)
13.5.7. Market Revenue and Forecast, by End-User (2021-2034)
13.5.8. Rest of LATAM
13.5.8.1. Market Revenue and Forecast, by Product Type (2021-2034)
13.5.8.2. Market Revenue and Forecast, by Platform (2021-2034)
13.5.8.3. Market Revenue and Forecast, by Mode of Purchase (2021-2034)
13.5.8.4. Market Revenue and Forecast, by Testing Type (2021-2034)
13.5.8.5. Market Revenue and Forecast, by End-User (2021-2034)
14.1. Abbott Laboratories
14.1.1. Company Overview
14.1.2. Product Offerings
14.1.3. Financial Performance
14.1.4. Recent Initiatives
14.2. Roche Diagnostics
14.2.1. Company Overview
14.2.2. Product Offerings
14.2.3. Financial Performance
14.2.4. Recent Initiatives
14.3. Siemens Healthineers
14.3.1. Company Overview
14.3.2. Product Offerings
14.3.3. Financial Performance
14.3.4. Recent Initiatives
14.4. Johnson & Johnson
14.4.1. Company Overview
14.4.2. Product Offerings
14.4.3. Financial Performance
14.4.4. Recent Initiatives
14.5. Danaher Corporation
14.5.1. Company Overview
14.5.2. Product Offerings
14.5.3. Financial Performance
14.5.4. Recent Initiatives
14.6. Becton, Dickinson and Company (BD)
14.6.1. Company Overview
14.6.2. Product Offerings
14.6.3. Financial Performance
14.6.4. Recent Initiatives
14.7. Philips Healthcare
14.7.1. Company Overview
14.7.2. Product Offerings
14.7.3. Financial Performance
14.7.4. Recent Initiatives
14.8. Sysmex Corporation
14.8.1. Company Overview
14.8.2. Product Offerings
14.8.3. Financial Performance
14.8.4. Recent Initiatives
14.9. Quidel Corporation
14.9.1. Company Overview
14.9.2. Product Offerings
14.9.3. Financial Performance
14.9.4. Recent Initiatives
14.10. Chembio Diagnostics
14.10.1. Company Overview
14.10.2. Product Offerings
14.10.3. Financial Performance
14.10.4. Recent Initiatives
15.1. Primary Research
15.2. Secondary Research
15.3. Assumptions
16.1. About Us
16.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample